Objective-To determine the molecular mechanism underlying the synergistic response of mitogen-activated protein kinase phosphatase-1 (MKP-1), which is induced by thrombin and epidermal growth factor (EGF). 
I
t was previously shown that mitogen-activated protein (MAP) kinase phosphatase-1 (MKP-1) is a key signaling mediator in thrombin-and vascular endothelial cell (EC) growth factor (VEGF)-mediated activation of ECs. 1, 2 Furthermore, MKP-1 plays a positive role in atherogenesis in a mouse model. 3 MKP-1 inactivates MAP kinases by the dephosphorylation of both threonine and tyrosine residues, 4 but other substrates also exist. Recently, it was shown that MKP-1 dephosphorylates serine 10 of histone H3. 5 MKP-1 has been stimulated under conditions that occur during inflammation and stress, 6, 7 but multiple studies have also demonstrated MKP-1 to be an anti-inflammatory molecule. 8, 9 Thrombin receptors couple to multiple G proteins and activate extracellular signal-regulated kinase (ERK), p38, and JNK in ECs. 10, 11 These signaling pathways ultimately lead to the activation of transcription factors that mediate the induction of a variety of pathophysiologically important genes. Thrombin also causes the transactivation of the EGF receptor (EGFR) by tyrosine phosphorylation. 12 Multiple studies have shown that thrombin and other G-proteincoupled receptors elicit their biological function, at least in part, via the transactivation of EGFR. 13 G protein coupled receptors (GPCRs) and receptor tyrosine kinases, such as EGFRs, have been involved in the progression of a variety of diseases. 14, 15 EC migration is an early event in inflammatory angiogenesis and normal vasculogenesis. Recently, it was demonstrated that MKP-1 is a key signaling mediator in VEGF-induced EC migration. 2 Herein, we extend the previous study and demonstrate, for the first time to our knowledge, that thrombin or lysophosphatidic acid (LPA) induction of MKP-1 is synergistically increased by EGF in ECs. We have elucidated the signaling mechanism responsible for the synergy and demonstrated that VEGF receptor (VEGFR)-2 activity is critical for the synergistic induction of MKP-1 by thrombin and EGF.
A real-time PCR assay was performed to determine pre-mRNA of MKP-1. The MKP-1-specific primers included (1) an intron-specific forward primer (5Ј-AGT ACA TTT ATC TCT GGA AC-3Ј) and (2) an exon-specific reverse primer (5Ј-CGT AGA GTG GGG TAC TGC AG-3Ј). Metalloproteinase inhibitor BB3103 was also used in the present study.
Results

Synergistic Induction of MKP-1 by Thrombin Plus EGF
It was previously shown that thrombin induces MKP-1 in ECs via protease-activated receptor-1 (PAR-1), the predominant thrombin receptor present in human ECs. 1 Some PAR-1-mediated cellular events have been reported to be due to transactivation of EGFR. 17 We reasoned that if the induction of MKP-1 by thrombin was mediated by EGFR transactivation, then EGF alone might also induce MKP-1 in ECs. To test this hypothesis, we treated ECs with EGF in the presence or absence of thrombin and measured MKP-1 mRNA by Northern blot analysis. As shown in Figure 1A , EGF treatment, 16 ng/mL, resulted in only a small fraction of the thrombin response; however, we observed a robust MKP-1 induction when ECs were treated with thrombin and EGF in combination. We tested EGF at various concentrations, ranging from 1 to 100 ng/mL; and the MKP-1 expression reached a maximum response at 16 ng/mL (approximately 2-fold; data not shown). This result excluded the possibility that the minimal effect of EGF in MKP-1 induction in ECs was due to a suboptimal EGF concentration. As shown in Figure 1B , thrombin or EGF treatment resulted in an approximate 4-or 2-fold increase, respectively, in the MKP-1 message; thrombin plus EGF increased the MKP-1 message synergistically (approximately 12-fold). The kinetics of the response to the combined agonists were similar to those of either agonist alone ( Figure 1C) .
We also examined MKP-1 protein levels under these conditions. Because the commercial antibodies to MKP-1 were not sensitive enough to detect MKP-1 by either Western analysis or immunoprecipitation in human ECs, we used mouse aortic ECs. MKP-1 protein was increased by approximately 2-and 3-fold by EGF and thrombin, respectively, with an 8.0-fold increase by thrombin plus EGF (supplemental Figure I ). Similar to thrombin, agents such as LPA, lysophosphatidylcholine (LPC), and endothelin-1 are pathophysiologically important agonists that elicit their biological effects via activation of their respective GPCRs. LPA, but not LPC or endothelin-1, increased MKP-1 gene induction (supplemental Figure II) . Furthermore, LPA plus EGF showed synergy in MKP-1 induction, similar to thrombin receptoractivating peptide (TRAP)-1 plus EGF.
Then, we determined the effect of TRAP-1 alone or in combination with EGF on ERK activation ( Figure 1D and E). TRAP-1 induced a rapid, but moderate, activation of ERK. EGF treatment resulted in a robust activation of ERK within 5 minutes, peaking at 20 minutes (approximately 3.7-fold) and persisting (Ͼ2-fold) for up to 180 minutes. The combination of TRAP-1 and EGF caused more rapid ERK dephos- A, Confluent cultures of umbilical vein ECs were serum starved for 2 hours before thrombin, 5 U/mL; EGF, 16 ng/mL; or thrombin plus EGF at 37°C for 1 hour. Cells were lysed, and 10 g of total RNA was subjected to Northern blot analysis using MKP-1 or ribosomal protein L-32 (RPL-32, loading control) probes. B, Quantitative analysis of 3 independent experiments performed as described in A. C, The kinetics of MKP-1 mRNA induction by TRAP-1, EGF, or TRAP-1 plus EGF were determined by quantitative real-time PCR. The fold induction was quantified relative to the untreated control. D, Kinetics of ERK activation. Western blotting was performed either with phosphorylated ERK1/2 (pERK)-, ERK-, or GAPDHspecific antibodies. E, Quantification of the ERK activation from 3 separate immune blots, normalized to the GAPDH and expressed as fold induction compared with the untreated condition.
phorylation, as would be expected from the increased levels of MKP-1. The activation profiles of p38 and JNK by TRAP-1, EGF, or EGF plus TRAP-1 were similar to ERK activation (data not shown).
MKP-1 Induction by Thrombin Plus EGF Is PAR-1 Dependent, EGFR Kinase Activity Dependent, and Matrix Metalloproteinase Independent
The synergistic induction of MKP-1 by PAR-1-specific agonistic peptide (TRAP-1 or SFLLRNP) and EGF is shown in Figure 2A . Peptides specific to PAR-4 (AYPGKF) or PAR-2 (SLIGKV) independently or in combination with EGF failed to induce MKP-1 induction (data not shown). AG1478, a specific EGFR kinase inhibitor, completely blocked EGFinduced MKP-1; it partially blocked the TRAP-1 plus EGF response. Furthermore, AG1478 did not inhibit TRAP-1-induced MKP-1 ( Figure 2B ). Quantification of multiple Northern blot analyses revealed that MKP-1 mRNA levels in the EGF plus TRAP-1-treated ECs in the presence of AG1478 were equivalent to MKP-1 mRNA in the presence of TRAP-1 alone ( Figure 2C ). In the presence of AG1478, the TRAP-1 plus EGF-induced MKP-1 mRNA level (approximately 12-fold) was reduced to approximately 3.5-fold; the latter was equivalent to TRAP-1 alone-mediated MKP-1 induction. These results suggest that the synergy in MKP-1 induction by thrombin plus EGF is the result of convergence of 2 independent signaling pathways. The combination of an AG1478-insensitive PAR-1 signal and an AG1478-sensitive EGFR pathway resulted in the synergistic induction of MKP-1.
GPCR-mediated matrix metalloproteinase activation releases a membrane-bound EGF family of ligands that, in turn, activate the EGFR. 13 To determine whether matrix metalloproteinases are involved in the synergistic induction of MKP-1, we treated ECs with TRAP-1 plus EGF in the presence of BB3103 (British Biotech Pharmaceuticals, Oxford, UK), a specific inhibitor of matrix metalloproteinases and determined MKP-1 mRNA level by Northern blot analysis. As shown in Figure 2D , BB3103 pretreatment did not block MKP-1 induction by TRAP-1 or EGF individually or in combination. We verified the inhibitory activity of BB3103 independently by inhibiting matrix metalloproteinase enzyme activity in thrombin-treated cell extracts using in-gel collagen degradation (data not shown). These results suggest that an intracellular link between the PAR-1 and EGFR signaling pathways is responsible for thrombin plus EGF-mediated synergy in MKP-1 induction.
Two Distinctive PAR-1 Pathways Are Required for Synergy in MKP-1 Induction by Thrombin Plus EGF
PAR-1 and EGFR are known to activate Src family kinases and downstream MAP kinases. 2, 17 It was previously demonstrated that the Src family of kinases and MAP kinases are critical for thrombin and VEGF induction of MKP-1 in ECs. 1, 2 The inhibitor of the Src family of kinases, PP1, blocked both TRAP-1 and TRAP-1 plus EGF-induced MKP-1 in ECs ( Figure 3A) . Then, we determined the involvement of specific Src kinase family members in the synergistic induction of MKP-1. As shown in Figure 3B , the depletion of c-Src considerably diminished the synergy portion of the induction, without blocking TRAP-1-induced MKP-1; depletion of Fyn significantly reduced both TRAP-1-and TRAP-1 plus EGF-mediated MKP-1 induction. ERK inhibitor PD98059 prevented TRAP-1 induction of MKP-1; it only partially inhibited TRAP-1 plus EGF-induced MKP-1, and it did not at all inhibit the induction of MKP-1 by EGF ( Figure 3C ). In the TRAP-1 plus EGF group, the reduction in the amount of MKP-1 mRNA by PD98059 (an approximate 12-fold induction was reduced to an approximate 9-fold induction in the presence of PD98059) was similar to the level of MKP-1 mRNA induced by TRAP-1 alone (approximately 3.5-fold) ( Figure 3D ). These results suggest that 2 distinct signals (1 ERK dependent and 1 ERK independent) from the PAR-1 receptor were required for the synergy in MKP-1 induction.
Synergy in MKP-1 Induction by Thrombin Plus EGF Is at the Transcriptional Level
It was shown earlier that thrombin induction of MKP-1 is at the transcriptional level. 1 The synergistic induction of MKP-1 mRNA in the presence of EGF could be due to mRNA stabilization or increased transcription. We tested for a change in mRNA stability by treating ECs with vehicle, TRAP-1, EGF, or TRAP-1 plus EGF for 1 hour, followed by treatment with actinomycin D. As shown in Figure 4A , compared with the control condition, TRAP-1, EGF, or TRAP-1 plus EGF caused no significant change in the half-life of MKP-1 mRNA. In a complementary approach, we measured the unspliced form of the MKP-1 transcript (MKP-1 premRNA) by quantitative real-time PCR using an intron-specific forward primer and an exon-specific reverse primer. At 1 hour, TRAP-1 and EGF upregulated MKP-1 premRNA by approximately 5-and 3-fold, respectively; TRAP-1 plus EGF showed an approximate 12-fold increase in MKP-1 pre-RNA ( Figure 4B ). This relative increase in the abundance of premRNA by TRAP-1 plus EGF points to an increase in the transcription rate.
Synergistic Induction of MKP-1 by Thrombin Plus EGF Requires VEGFR-2
It was previously reported that VEGF induces MKP-1 more effectively than thrombin in ECs. 2 Herein, we determined the effect of VEGF on TRAP-1, LPA, and/or EGF on MKP-1 induction. We identified an additive effect in MKP-1 induction when cells were treated with TRAP-1 or LPA in the presence of VEGF ( Figure 5A ). TRAP-1 or LPA induction of MKP-1 was approximately 5-fold, and VEGF induction alone was approximately 12-fold. Thrombin or LPA plus VEGF induction was approximately 17-fold; furthermore, this additive effect was similar in quantity to the synergistic effect induced by TRAP-1 plus EGF (17-fold). VEGF did not augment TRAP-1 plus EGF induction of MKP-1. TRAP-1 plus LPA induction was similar to either of them alone, suggesting overlapping signaling pathways from the thrombin and LPA receptors in MKP-1 induction.
JNK, not ERK, activation was critical for VEGF induction of MKP-1. 2 Because VEGF induction was similar to ERK- independent thrombin plus EGF-mediated MKP-1 induction (approximately 12-fold), we next determined the role of JNK in thrombin plus EGF-induced MKP-1. As shown in Figure  5B , a JNK inhibitor blocked most of the observed synergy, and the uninhibited portion was equivalent to ERK-dependent thrombin induction. Simultaneous inhibition of both the ERK and JNK pathways blocked the synergistic effect almost completely. In a corollary experiment, TRAP-1 plus VEGFinduced MKP-1 was blocked completely by ERK and JNK inhibitors. ERK or JNK inhibitors brought the level of MKP-1 induction down to the thrombin or VEGF alone levels, respectively. By using specific neutralizing antibodies to various VEGFRs, it was previously demonstrated that VEGFR-2 is responsible for VEGF-induced MKP-1 induction. 2 Therefore, we next tested the role of VEGFR-2, if any, in MKP-1 induction by thrombin plus EGF. The synergistic induction of MKP-1 by TRAP-1 plus EGF was substantially reduced in the VEGFR-2-depleted cells, using VEGFR-2-specific small interfering RNA ( Figure 5C ). VEGFR-2 depletion did not alter MKP-1 induction by TRAP-1 alone. Furthermore, the VEGFR-2 kinase inhibitor ZM323881 showed similar results because it blocked the synergistic MKP-1 induction but not the TRAP-1 alone induction ( Figure 5D ). These results indicate that VEGFR activation is one of the downstream events to our identified ERK-independent pathway. Previous studies in other cell types have demonstrated VEGF gene expression by EGF and that the secreted VEGF activated VEGFR in an autocrine fashion. 18 It was previously shown that, among the various VEGF isotypes, only VEGF-A induces MKP-1. 2 In Figure 5E , a neutralizing antibody specific to VEGF-A did not block thrombin plus EGF-induced MKP-1, suggesting that the mechanism of VEGFR activation is not due to secreted VEGF-A and the subsequent autocrine activation of VEGFR. We failed to coimmunoprecipitate EGFR and VEGFR-2 in the presence or absence of agonists, although we believe our conditions were appropriate because we successfully coimmunoprecipitated a different heterologous membrane receptor pair (EGFR and human epidermal growth factor receptor [HER]-2) (data not shown). These results suggest that the synergistic induction of MKP-1 was not the result of EGFR and VEGFR-2 heterodimerization. 
TRAP-1 Plus EGF-Mediated Gene Regulation and EC Migration
It was previously reported that ERK activation is required for thrombin induction of PDGFA, E-selectin, and vascular cell adhesion molecule; PDGFB induction was negatively regulated by ERK activity. 1 We now demonstrate that the combination of TRAP-1 and EGF results in a lower level of induction of PDGFA, E-selectin, and vascular cell adhesion molecule-1 compared with TRAP-1 alone; PDGFB induction was further increased when ECs were treated with TRAP-1 in combination with EGF (supplemental Table I ). The changes were largely unaffected by ERK inhibition, which is likely because the increased MKP-1 has already reduced ERK activity.
Recently, using in vitro assays, we demonstrated a positive role of MKP-1 in VEGF-induced EC migration and angiogenesis. 2 In a transwell assay system, TRAP-1 plus EGF caused a greater level of EC migration compared with either agonist alone. (Figure 6A ). The average increase in EC migration induced by TRAP-1 alone was moderate (Ͻ2-fold), and EGF alone yielded an approximate 4-fold increase (PϽ0.05) ( Figure 6B) ; TRAP-1 plus EGF treatment resulted in an approximate 8-fold increase (PϽ0.01). MKP-1 depletion, using a specific small interfering RNA, blunted TRAP-1-stimulated EC migration but had no significant effect on the response to EGF ( Figure 6C ). MKP-1-specific small interfering RNA diminished TRAP-1 plus EGF-induced cell migration to the level equivalent to that of EGF alone (from approximately 8-to approximately 4-fold, PϽ0.01). Thus, PAR-1 or PAR-1 plus EGFR-mediated EC migration is critically dependent on MKP-1 activity; EGF alone-induced migration is MKP-1 independent.
Discussion
Recent reports 1,2 describe the induction of MKP-1 by thrombin or VEGF by distinct pathways and the role of this dual-specificity phosphatase in EC gene expression and migration. Herein, we report that thrombin or LPA treatment with EGF resulted in the synergistic induction of MKP-1 in ECs. This strong induction of MKP-1 has significant implications in vascular homeostasis and diseases because MKP-1 and agonists such as thrombin, LPA, VEGF, or EGF and their cognate receptors are known to be present in the vessel wall during development and under various injury or chronic disease conditions, such as atherosclerosis. 3,19 -22 The receptors for thrombin, LPA, LPC, and endothelin-1 are GPCRs and have induced both common and distinct signaling pathways and elicit sometimes similar and sometimes distinctive biological end points. 23 Herein, we demonstrated that MKP-1 induction was restricted to thrombin and LPA and not to LPC or endothelin-1. Furthermore, signaling pathways to induce MKP-1 by thrombin or LPA and either 1 of them with EGF were similar (supplemental Table II ), suggesting that MKP-1 is a prototypical example of common signaling end points of the thrombin and LPA receptors.
Two mechanisms have been hypothesized to explain the signaling cross-talk between GPCRs and receptor tyrosine kinases. Prenzel et al 24 showed evidence that GPCR activation led to metalloproteinase-mediated EGFR ligand release from the EC surface, leading to activation of EGFR in an autocrine or paracrine manner. Alternatively, on GPCR activation, the Src family of proteins or G-protein subunits may physically interact with the cytosolic domain of EGFR, resulting in the triggering of the downstream EGFR signaling cascade. 25, 26 In this study, we have shown a novel metalloproteinase activity-independent, but EGF-dependent, signaling interaction between the thrombin or LPA receptor and EGFR, resulting in MKP-1 induction in ECs. We identified a requirement for both ERK-dependent and ERK-independent pathways originating from the activated GPCR for the full induction of MKP-1 when ECs are treated with thrombin or LPA plus EGF. The synergy in MKP-1 induction by thrombin or LPA plus EGF is because of the net effect of such converging signals. In the classic MAP kinase pathway, the Src family of kinases is upstream to Raf, Ras, MAPK/ERK kinase (MEK), and ERK; our inhibitor studies suggest that this pathway is responsible for the thrombin or LPA induction of MKP-1. 27 The ERK-independent pathway responsible for the synergy is more complex. We determined that JNK activity and VEGFR-2 are involved in the ERK-independent pathway. It was previously shown that JNK is a downstream signaling intermediate in VEGF-induced MKP-1 induction. 2 EGFR activation was shown to induce VEGF gene expression and secretion. 28 However, a neutralizing antibody to VEGF-A, the only VEGFR ligand capable of inducing MKP-1 2 in ECs, did not prevent thrombin plus EGF-induced MKP-1. Furthermore, the ERK-independent pathway from the thrombin receptor alone is not sufficient to induce MKP-1; a signaling component from EGFR is also required. We believe that the ERK-independent pathway induced by thrombin plus EGF converges at VEGFR intracellularly, resulting in MKP-1 induction. Signaling interactions between GPCRs and various receptor tyrosine kinases are well-known. Recently, Greenberg et al 29 have demonstrated that activated VEGFR blocks PDGFB receptor activity and PDGF-induced neovascularization. To our knowledge, signaling interactions between GPCR, EGFR, and VEGFR, resulting in the transcriptional activation of a gene, have not been reported. Furthermore, our results emphasize the significance of interplay among the bioactive molecules in the vascular microenvironment.
